» Authors » Ayuko Ota-Setlik

Ayuko Ota-Setlik

Explore the profile of Ayuko Ota-Setlik including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 758
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Vogel A, Kanevsky I, Che Y, Swanson K, Muik A, Vormehr M, et al.
Nature . 2021 Feb; 592(7853):283-289. PMID: 33524990
A safe and effective vaccine against COVID-19 is urgently needed in quantities that are sufficient to immunize large populations. Here we report the preclinical development of two vaccine candidates (BNT162b1...
2.
Clarke D, Xu R, Matassov D, Latham T, Ota-Setlik A, Gerardi C, et al.
Lancet Infect Dis . 2020 Jan; 20(4):455-466. PMID: 31952923
Background: The safety and immunogenicity of a highly attenuated recombinant vesicular stomatitis virus (rVSV) expressing HIV-1 gag (rVSVN4CT1-HIV-1gag1) was shown in previous phase 1 clinical studies. An rVSV vector expressing...
3.
Cross R, Xu R, Matassov D, Hamm S, Latham T, Gerardi C, et al.
J Clin Invest . 2019 Dec; 130(1):539-551. PMID: 31820871
Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of...
4.
Pittala S, Bagley K, Schwartz J, Brown E, Weiner J, Prado I, et al.
Mol Syst Biol . 2019 May; 15(5):e8747. PMID: 31048360
Characterizing the antigen-binding and innate immune-recruiting properties of the humoral response offers the chance to obtain deeper insights into mechanisms of protection than revealed by measuring only overall antibody titer....
5.
Elizaga M, Li S, Kochar N, Wilson G, Allen M, Tieu H, et al.
PLoS One . 2018 Sep; 13(9):e0202753. PMID: 30235286
Background: The addition of plasmid cytokine adjuvants, electroporation, and live attenuated viral vectors may further optimize immune responses to DNA vaccines in heterologous prime-boost combinations. The objective of this study...
6.
Suksanpaisan L, Xu R, Tesfay M, Bomidi C, Hamm S, Vandergaast R, et al.
Mol Ther Oncolytics . 2018 Jul; 10:1-13. PMID: 29998190
Immunotherapy for HPV malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including...
7.
Matassov D, Mire C, Latham T, Geisbert J, Xu R, Ota-Setlik A, et al.
J Virol . 2017 Nov; 92(3). PMID: 29142131
Previous studies demonstrated that a single intramuscular (i.m.) dose of an attenuated recombinant vesicular stomatitis virus (rVSV) vector (VesiculoVax vector platform; rVSV-N4CT1) expressing the glycoprotein (GP) from the Mayinga strain...
8.
Li S, Kochar N, Elizaga M, Hay C, Wilson G, Cohen K, et al.
Clin Vaccine Immunol . 2017 Sep; 24(11). PMID: 28931520
The HIV Vaccine Trials Network (HVTN) 087 vaccine trial assessed the effect of increasing doses of pIL-12 (interleukin-12 delivered as plasmid DNA) adjuvant on the immunogenicity of an HIV-1 multiantigen...
9.
Bagley K, Schwartz J, Andersen H, Eldridge J, Xu R, Ota-Setlik A, et al.
Viral Immunol . 2017 Jan; 30(3):178-195. PMID: 28085634
Vaccination is a proven intervention against human viral diseases; however, success against Herpes Simplex Virus 2 (HSV-2) remains elusive. Most HSV-2 vaccines tested in humans to date contained just one...
10.
Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, et al.
J Infect Dis . 2015 Jun; 212 Suppl 2:S443-51. PMID: 26109675
Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolavirus glycoproteins (GPs) in place of the VSV G protein demonstrated protection of nonhuman primates from lethal homologous Ebolavirus challenge. Those pseudotype...